Stock Story: Neuren Pharmaceuticals

n March, the US Food and Drug Administration (FDA) approved Australian company Neuren Pharmaceuticals’ and its US partner Acadia Pharmaceuticals’ drug for the treatment of Rett syndrome in the US. The drug, Daybue, is the first and only FDA-approved treatment for Rett syndrome, a rare and severe neurodevelopmental disorder that primarily affects young girls.

Disclaimer: Milford is an active manager with views and portfolio positions subject to change. This blog is intended to provide general information only. It does not take into account your investment needs or personal circumstances. It is not intended to be viewed as investment or financial advice. Should you require financial advice you should always speak to a Financial Adviser. Past performance is not a guarantee of future performance.

Видео Stock Story: Neuren Pharmaceuticals канала Milford